Abstract
In a phase-I-study recombinant interleukin-2 (rIL-2) in a dose from 0.01 to 0.3 mg/m2/day for 7 to 14 days was infused intraperitoneally. Side effects were fever and fluid retention. 2 patients showed a bacterial peritonitis after paracentesis. The investigations showed that the intraperitoneal (i.p.) administration of interleukin-2 activates the whole lymphokine cascade.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Catheters, Indwelling
-
Drug Evaluation
-
Female
-
Gastrointestinal Neoplasms / therapy*
-
Humans
-
Infusions, Parenteral / instrumentation
-
Interleukin-2 / administration & dosage*
-
Ovarian Neoplasms / therapy*
-
Peritoneal Neoplasms / secondary*
-
Peritoneal Neoplasms / therapy
-
Recombinant Proteins / administration & dosage
Substances
-
Interleukin-2
-
Recombinant Proteins